225 related articles for article (PubMed ID: 30006143)
21. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
Ren J; Shi W; Zhao D; Wang Q; Chang X; He X; Wang X; Gao Y; Lu P; Zhang X; Xu H; Zhang Y
Bioorg Med Chem; 2020 Jan; 28(2):115236. PubMed ID: 31843459
[TBL] [Abstract][Full Text] [Related]
23. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.
Liu L; Shi B; Li X; Wang X; Lu X; Cai X; Huang A; Luo G; You Q; Xiang H
Bioorg Med Chem; 2018 Aug; 26(15):4537-4543. PubMed ID: 30077608
[TBL] [Abstract][Full Text] [Related]
25. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
Xue Y; Song P; Song Z; Wang A; Tong L; Geng M; Ding J; Liu Q; Sun L; Xie H; Zhang A
J Med Chem; 2018 May; 61(10):4608-4627. PubMed ID: 29715023
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma.
Wu B; Yang S; Deng T; Wang C; Jin Y; Yu J; Xu Y; Chen L; Li Y; Ma X
Bioorg Chem; 2021 Nov; 116():105330. PubMed ID: 34547646
[TBL] [Abstract][Full Text] [Related]
28. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
Zheng N; Pan J; Hao Q; Li Y; Zhou W
Bioorg Med Chem; 2018 May; 26(8):2165-2172. PubMed ID: 29567295
[TBL] [Abstract][Full Text] [Related]
30. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
Huang W; Wang S; Zhang Z; Zhang C; Zeng S; Liang M; Shen Z; Liu X
Bioorg Chem; 2020 Dec; 105():104377. PubMed ID: 33091668
[TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase.
Zhang D; Xu G; Zhao J; Wang Y; Wu X; He X; Li W; Zhang S; Yang S; Ma C; Jiang Y; Ding Q
Eur J Med Chem; 2021 Dec; 225():113724. PubMed ID: 34391034
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
35. Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors.
Lin TE; Sung LC; Chao MW; Li M; Zheng JH; Sung TY; Hsieh JH; Yang CR; Lee HY; Cho EC; Hsu KC
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):226-235. PubMed ID: 34894949
[TBL] [Abstract][Full Text] [Related]
36. Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Sun B; Liu X; Zheng X; Wang C; Meng Q; Sun H; Shu X; Liu K; Sun X; Li Y; Ma X
ChemMedChem; 2020 Jan; 15(2):182-187. PubMed ID: 31755225
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
Caldwell R; Liu-Bujalski L; Qiu H; Mochalkin I; Jones R; Neagu C; Goutopoulos A; Grenningloh R; Johnson T; Sherer B; Gardberg A; Follis AV; Morandi F; Head J
Bioorg Med Chem Lett; 2018 Nov; 28(21):3419-3424. PubMed ID: 30290988
[TBL] [Abstract][Full Text] [Related]
38. Development of BTK inhibitors for the treatment of B-cell malignancies.
Kim HO
Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
